Abstract
In several neuropathological conditions, αB-crystallin and glial fibrillary acidic protein (GFAP) accumulate and form cytoplasmic inclusions in astrocytes. To explore the pathogenesis of the inclusions and the possible functions of the accumulated αB-crystallin, GFAP and αB-crystallin were overexpressed in cultured astrocytes by transient transfection. Human GFAP formed filamentous, cytoplasmic inclusions in mouse astrocytes, NIH3T3 cells, rat C6 glioma cells, and human U251 glioma cells. These human GFAP inclusions did not contain the endogenous vimentin or β-tubulin, and the intermediate filament and microtubular networks of the transfected cells appeared normal. αB-crystallin and hsp25 were associated with the GFAP inclusions. Increasing intracellular αB-crystallin levels using recombinant adenoviruses, either before or after GFAP inclusions were formed, decreased the number of inclusion-bearing astrocytes and converted the human GFAP from an inclusion to a spread, filamentous form. These results suggest that αB-crystallin reorganizes abnormal intermediate filament aggregates into the normal filamentous network.
αB-crystallin, a structural component of the vertebrate lens, belongs to a family of small heat shock proteins (hsps). αB-crystallin is expressed constitutively at high levels in tissues such as cardiac and skeletal muscle and kidney 1-3 but is inducible in many cell types by a variety of physiological stresses. 4-6 αB-crystallin prevents heat-induced aggregation of protein molecules in vitro 7 and protects cells from damage caused by thermal and osmotic stresses. 4,8,9 The mechanism(s) by which αB-crystallin exerts protective effects is not clear, although interactions with cytoskeletal proteins has been suggested to be important. 10 For example, αB-crystallin stabilizes filamentous actin organization in glioma cells. 8 In vitro, the association of αB-crystallin with F-actin prevents depolymerization. 11 With respect to intermediate filaments (IFs), interactions between αB-crystallin and IFs have been noted in muscle, lens, and astrocytes. 12-14 In vitro, αB-crystallin inhibits the polymerization of IFs, 13 but whether this small hsp plays any role in the polymerization or organization of IFs in situ is unknown.
In a number of disorders, IFs form abnormal cytoplasmic aggregates, such as the Mallory bodies of hepatic cirrhosis, 15 Lewy bodies of Parkinson disease, 16 and Rosenthal fibers (RFs ) 17-21 of Alexander disease, chronic glial scars, and low-grade, fibrillary astrocytomas. All of these IF inclusions also contain αB-crystallin, 1,22,23 suggesting that there is some affinity between the proteins or that cells up-regulate small hsps in response to filament pathology. The latter idea is consistent with recent findings in transgenic mice that express the human GFAP (hGFAP) gene regulated by its own promoter. 24 Astrocytes of these mice become hypertrophic and develop cytoplasmic inclusions similar or identical to RFs. Levels of the endogenous αB-crystallin and hsp27 mRNA are elevated, although levels of hsp70 mRNA remain normal in these brains, suggesting that the accumulation of IFs somehow induces a cellular stress reponse specific to small hsps. Furthermore, astrocytes cultured from the brains of the transgenic mice formed RFs without additional stress conditions, 25 suggesting that overexpression of hGFAP is sufficient to induce the IF-containing inclusions in mouse astrocytes.
In this study, we explore the generation of IF inclusions and show that hGFAP transfected into mouse astrocytes forms inclusions separate from the endogenous IF network. In addition, to examine the effects of αB-crystallin on such inclusions, we introduced αB-crystallin into inclusion-bearing astrocytes. However, rather than forming RFs, the αB-crystallin acted to disperse the GFAP in the inclusions into the normal filamentous array. Thus, astrocytes may up-regulate small hsps as a response to abnormal IF organization in an attempt to restore the normal IF network.
Materials and Methods
Cell culture
Astrocyte cultures were prepared from forebrains of 1- to 2-day-old C57BL mice according to previously described methods. 6 Dissociated cells were seeded on 75-cm 2 culture flasks at 2 × 10 5 cells/cm 2 and cultured in Eagle’s minimal essential medium (MEM) supplemented with 5% fetal calf serum (FCS), 100 U/ml penicillin G, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin B, and 0.5% d-glucose. After cells reached confluence (∼10 days), the small process-bearing oligodendrocyte progenitor cells and the microglia were removed by rotatory shaking. The remaining monolayer of astrocytes were used 12 to 24 days after initial seeding. Rat C6 glioma and human U251 astrocytoma lines were cultured in Dulbecco’s MEM (DMEM) supplemented with 10% FCS. NIH3T3 cells were cultured in DMEM supplemented with 5% calf serum.
Expression Vectors
An expression vector for hGFAP, RSVi-hGF, and the parent plasmid pRSVi-HindIII were generous gifts from Dr. Ron Liem (Columbia University, New York, NY). The HindIII cloning site in pRSVi-HindIII positions at the 3′ flanking region of the RSV long-term repeat. RSVi-hGF has a full-length protein-encoding region of human GFAP cDNA at the HindIII site in pRSVi-HindIII. 26 An expression vector for mouse GFAP, RSVi-mGF, was constructed from a full-length protein-encoding region of mouse GFAP cDNA, which was obtained as a BamHI fragment of mouse GFAP cDNA clone, pGfa-mGfa2 (a gift from Dr. M. Brenner, National Institutes of Health, Bethesda, MD). The BamHI fragment was blunt-ended by T4 DNA polymerase and ligated to HindIII linkers. After the ligated linkers were digested by HindIII, the mouse GFAP fragment was subcloned into the HindIII site of pRSVi-HindIII to make RSVi-mGF. An expression vector for E. coli β-galactosidase (β-Gal), pSVβ-Gal, was purchased from Promega (Madison, WI).
Recombinant adenovirus vectors carrying the rat αB-crystallin cDNA in the sense orientation or the β-Gal gene (αBSAD and β-GalAD, gifts from Drs. Jody Martin and Wolfgang Dillman, University of California, San Diego, San Diego, CA) were described previously. 27 In each vector, the transgene is driven by the CMV promoter/enhancer and flanked by an SV40 polyadenylation signal. Amplification, purification, and titration of these vectors were performed according to previously described methods. 27
Transfection with Vectors
One day before transfection, cultured cells were trypsinized and plated on glass coverslips (12-mm diameter) coated with 20 μg/ml poly-l-lysine in 24-well culture plates. The cell density was 0.5 × 10 5 cells/well for mouse astrocytes and 0.25 × 10 5 cells/well for NIH3T3, C6, and U251 cells. Transfections were performed using a polyamine transfection reagent (TransIT LT-1, PanVera, Madison, WI) according to the manufacturer’s protocol. In most experiments, 1 μg of GFAP expression vectors was used for each culture well. The polyamine reagent was diluted with OptiMEM (Gibco, Gaithersburg, MD) at 1:10, and the vectors were mixed with the diluted polyamine solution. After cells were rinsed with OptiMEM twice, 30 μl of the DNA/polyamine mixture was added to each well filled with 270 μl of OptiMEM. Cells were incubated for 8 hours at 37°C, and then the medium was changed to the respective growth medium. In the transfections of U251 with the hGFAP vector and of mouse astrocytes with the mouse GFAP vector, where endogenous GFAP prevents an immunohistochemical detection of vector-derived GFAP, co-transfection with the GFAP vectors and pSVβ-Gal at a 1:0.4 ratio was performed to distinguish the transfected cells.
Infections with Adenovirus Vectors
Astrocytes grown on coverslips in 24-well plates were infected with recombinant adenovirus vectors at a multiplicity of infection of 20. Purified adenoviral vectors were diluted in Eagle’s MEM supplemented with 2% FBS and astrocytes incubated in 200 μl for 45 minutes at room temperature. After incubation, 800 μl of MEM containing 10% FBS was added to the well. On the following day, the virus-containing medium was changed to the growth medium. We have found that 30% to 50% of cultured astrocytes expressed the transgene product after the adenovirus infection, and the transgene protein products remained at high levels for at least 6 weeks (MW Head, L Hurwitz, KB Kegel, and JE Goldman, submitted).
Immunocytochemistry
Two to fourteen days after transfection with GFAP expression vectors, cells were fixed with 3% paraformaldehyde in phosphate-buffered saline (PBS) for 30 minutes and permeabilized by 0.2% Nonidet P-40 (NP-40) in PBS for 7 minutes. In experiments to show accumulation of αB-crystallin and hsp25 in cytoskeletal components, cells were treated first with PBS containing 0.2% NP-40, 5 mmol/L MgCl2, and 3 mmol/L EGTA for 2 minutes before paraformaldehyde fixation. Cells transfected with the hGFAP vector were selectively labeled by a hGFAP-specific mouse monoclonal antibody (SMI21, Sternberger Monoclonals, Baltimore, MD), which does not recognize mouse GFAP. The hGFAP-specific antibody was diluted in PBS containing 5% goat serum and 0.01% NP-40 (1:1000 dilution), and fixed cells were incubated for 4 hours. Cells were then rinsed with PBS and subsequently incubated with rhodamine- or fluorescein-isothiocyanate-conjugated secondary antibody (1:100 dilution) for 2 hours. Coverslips were rinsed with PBS and mounted on slide glasses using Gel/Mount (Biomeda Corp., Foster City, CA). When hGFAP-expressing cells were double labeled, an additional primary antibody was included in the diluted hGFAP-specific antibody solution, and the appropriate fluorochrome-conjugated secondary antibody was used. Primary antibodies used for double labeling of hGFAP-expressing cells were anti-rat αB-crystallin rabbit serum (CM2), 6 anti-hsp25 (mouse homologue of hsp27) rabbit serum (StressGen Biotechnologies Corp., Victoria BC, Canada), anti-hsp70 rabbit serum (StressGen Biotechnologies), anti-ubiquitin rabbit serum (StressGen Biotechnologies), anti-β-tubulin mouse monoclonal antibody (3F3-G2, ICN Biomedicals, Costa Mesa, CA), anti-vimentin mouse monoclonal antibody (VIM13.2, Sigma Chemical Co., St. Louis, MO), and anti-β-Gal mouse antibody (Promega). To examine the organization of exogenous mouse GFAP, mouse astrocytes co-transfected with RSVi-mGF and pSVβ-Gal were double labeled with a pan-species anti-GFAP rabbit serum (ALD10) 28 and the anti-β-Gal antibody. GFAP organization of the β-Gal-expressing cells was then observed. Preabsorbed anti-αB-crystallin rabbit serum was prepared by incubating the serum with bovine lens α-crystallin (Sigma; 12.5 μg of α-crystallin per 1 μl of the antiserum) for 16 hours at 4°C.
Electron Microscopy
One day before transfection, astrocytes were plated on 35-mm culture dishes, and co-transfection with hGFAP and β-Gal was made as described. Two days after the transfection, cells were fixed with 2.5% glutaraldehyde and 0.5% paraformaldehyde in PBS for 20 minutes. Transfected astrocytes were identified by X-Gal staining. At this point, those cells that contained inclusions were clearly visible. After the X-Gal staining, the cells were post-fixed with 1% osmium tetroxide in PBS. The cells were dehydrated through a graded series of ethanol washes, infiltrated, and embedded in epoxy resin. After the resin had solidified, the plastic culture dish was broken up to release the resin containing the embedded cells. X-Gal-stained cells that contained inclusions were selected under a light microscope. The resin containing the transfected cells was blocked and mounted onto blank sectioning stubs. The specimens were sectioned with a Diatome diamond knife on a Sorvall model MT7000 ultramicrotome. Silver and gray interference colored sections were collected onto uncoated 200- and 300-mesh copper grids. The sections were stained with uranyl acetate and lead citrate and viewed with a JEOL model 1200EX transmission electron microscope operating at 80 kV.
Results
hGFAP Forms Intracytoplasmic Inclusions in Astrocytes
hGFAP expressed in mouse astrocytes after transfection was organized in two distinct patterns. In some cells, hGFAP took on a filamentous pattern, identical to the endogenous IF network (Figure 1A) ▶ . In other cells, however, the hGFAP was organized into one or more discrete inclusions, separate from the IF network (Figure 1, B and C) ▶ . Other cells showed both the filamentous and inclusion patterns simultaneously. The inclusions varied in their sizes, shapes, and numbers, although all were cytoplas- mic and showed sharp, rounded borders. Some transfected cells contained one large inclusion, usually around the nucleus, whereas other cells contained many small inclusions scattered throughout the cytoplasm. Inclusions were observed as dark bodies under phase-contrast microscopy (Figure 1D) ▶ . Treatment of cells with 0.2% NP-40 before fixation did not diminish the hGFAP inclusions, indicating that they are composed of detergent-insoluble, polymerized GFAP (see also electron microscopy, below). The inclusions appeared to be metabolically stable, as they were observed for at least 14 days after the transfection, and during that time, the percentage of transfected cells that bore inclusions did not change (Table 1) ▶ .
Figure 1.
Filamentous and inclusion forms of hGFAP in mouse astrocytes transfected with RSVi-hGF. Mouse astrocytes were transfected with a hGFAP expression vector, RSVi-hGF, and stained with the anti-human GFAP-specific antibody 2 days after transfection. Astrocytes showing three different types of hGFAP organization are astrocytes showing filamentous hGFAP but no inclusion (A), co-existence of filaments and inclusions of hGFAP (B), and hGFAP inclusions without filaments (C). D: Phase-contrast image of C. Bar, 20 μm
Table 1.
Organization of Vector-Derived hGFAP in Mouse Cultured Astrocytes, C6 Glioma, NIH3T3, and U251 Astrocytoma
% Total transfected cells | |||
---|---|---|---|
Inclusions (+), filamentous (−) | Inclusions (+), filamentous (+) | Inclusions (−), filamentous (+) | |
Mouse astrocytes | |||
2 days (4) | 11.9 ± 3.6 | 50.3 ± 3.9 | 37.9 ± 2.5 |
7 days (3) | 9.0 ± 1.4 | 63.1 ± 1.8 | 27.9 ± 0.6 |
14 days (3) | 15.7 ± 1.9 | 52.4 ± 5.4 | 31.9 ± 3.7 |
C6 (5) | 28.4 ± 3.5 | 46.1 ± 3.0 | 25.4 ± 3.7 |
NIH3T3 (4) | 3.0 ± 0.9 | 22.5 ± 3.8 | 74.5 ± 3.9 |
U251 (3) | 7.4 ± 1.1 | 25.2 ± 4.1 | 67.1 ± 4.7 |
Cells were transfected with RSVi-hGF as described in Materials and Methods. The transfected mouse cultured astrocytes were fixed and stained with an anti-hGFAP-specific antibody 2, 7, and 14 days after the transfection. C6, NIH3T3, and U251 were stained 2 days after transfection. The organization of hGFAP was observed by epifluorescence light microscopy. In each experiment, more than 60 transfected cells were observed. The transfected cells are classified into three types: cells with hGFAP inclusions and no filaments (inclusion(+)/filamentous(−)), with inclusion and filaments (inclusion(+)/filamentous(+)), and with filaments and no inclusions (inclusion(−)/filamentous(+)). The percentages of each type are expressed as percentages of the total hGFAP-expressing cells. Results are means ± SEM. Numbers of independent experiments are given in parentheses.
The formation of hGFAP inclusions did not appear to be cell-type or species specific, as they were formed in NIH3T3, C6 rat glioma, and U251 human astrocytoma cells (Figure 2, A–C) ▶ . However, the percentages of transfected cells that contained inclusions were small in NIH3T3 and U251 cells (Table 1) ▶ . The formation of inclusions did not appear to be specific for hGFAP. Transfection with a mouse GFAP expression vector, RSVi-mGF, induced cytoplasmic inclusions in mouse astrocytes (Figure 2D) ▶ and NIH3T3 cells.
Figure 2.
GFAP inclusions in NIH3T3, C6 glioma, U251 astrocytoma, and mouse astrocytes. NIH3T3 (A), C6 (B), and U251 (C) were transfected with RSV-hGF and stained with the anti-hGFAP specific antibody 2 days after the transfection. Mouse cultured astrocytes were transfected with mouse GFAP expression vector RSVi-mGF and stained with the pan-species anti-GFAP rabbit serum 2 days after the transfection (D). Bar, 20 μm.
To determine whether the endogenous IF network was disrupted in the inclusion-bearing astrocytes, we co-labeled with antibodies for hGFAP and vimentin (as the IF system in the cultured astrocytes contains both GFAP and vimentin, which co-polymerize). The vimentin network appeared normal, well spread, and indistinguishable from that of nontransfected astrocytes (Figure 3, A and B) ▶ . Vimentin was not found associated with the inclusions. Similarly, co-immunostaining with a β-tubulin antibody showed that the microtubule network was not disrupted and that tubulin was not found in the inclusions (Figure 3, C and D) ▶ .
Figure 3.
Vimentin and microtubule networks in RSVi-hGF transfected mouse astrocytes. Two days after the transfection with RSVi-hGF, organizations of microtubule and vimentin were observed. A) Vimentin staining; C: β-Tubulin staining; B and D: hGFAP staining of the same fields corresponding to A and C, respectively. Bar, 20 μm
Electron microscopic observations of the transfected astrocytes showed that the inclusions were uniform structures that excluded all organelles (Figure 4) ▶ . Individual 10-nm filaments were discernible but were not organized in any systematic way, such as bundles composed of parallel filaments, indicating a random organization. Some, but not all, of the inclusions appeared continuous with bundles of IFs (Figure 4B) ▶ .
Figure 4.
Electron microscopic observation of hGFAP inclusions in mouse astrocytes. Two days after the transfection with RSVi-hGF, astrocytes were fixed, stained by X-Gal, and embedded in epoxy resin. A: A hGFAP inclusion in mouse cultured astrocytes. G, hGFAP inclusion; N, nucleus; bar, 4 μm. B: Arrows indicate 10-nm filaments associated with the inclusion (G); *microtubules. Bar, 0.2 μm.
αB-Crystallin Disaggregates hGFAP Inclusions
αB-crystallin is expressed at low levels in astrocytes under non-stress conditions. 6 Most of the αB-crystallin is soluble and cytoplasmic, but a small proportion is tightly associated with the cytoskeleton, notably IFs. 14 Immunocytochemical staining of astrocytes transfected with the hGFAP vector and then treated with NP-40 before fixation showed a positive signal for αB-crystallin associated with the hGFAP inclusions (Figure 5, A and B) ▶ . The αB-crystallin staining of inclusions was not visualized in controls omitting primary antibody or with primary antibody preabsorbed with bovine lens αB-crystallin (data not shown). hGFAP inclusions also contained hsp25 (Figure 5, C and D) ▶ , but we did not see positive reactions with antibodies to hsp70 or ubiquitin (not shown). αB-crystallin and hsp27 signals were also noted over the nucleus (Figure 5, A and C) ▶ , as noted previously for αB-crystallin, 14 although what these proteins associate with is not known.
Figure 5.
Accumulation of αB-crystallin and hsp25 in hGFAP inclusions. Mouse astrocytes were transfected with RSVi-hGF, and immunohistochemical studies were performed 2 days after the transfection. To remove soluble, cytoplasmic αB-crystallin, cells were treated with 0.2% NP-40 containing PBS for 2 minutes before fixation. Localization of detergent-insoluble αB-crystallin and hsp25 in hGFAP-expressing cells was examined by double labeling with anti-hGFAP specific antibody. A: αB-crystallin staining; C: hsp25 staining; B and D: hGFAP staining of the same fields corresponding to A and C, respectively. Bar, 20 μm.
We then increased the levels of αB-crystallin in mouse astrocytes by infection with the αB-crystallin-expressing adenovirus vector αBSAD. Although the cultured astrocytes express low levels of αB-crystallin and the antibody does not discriminate between the endogenous mouse αB-crystallin and the (exogenous) rat αB-crystallin introduced by the vector, the infected cells clearly showed a far brighter signal (Figure 6C) ▶ . Adenovirus infection and expression was efficient, with 30% to 50% of the astrocytes showing high levels of αB-crystallin after infection. Western blotting of astrocyte cultures infected with the αBSAD show dramatically increased levels αB-crystallin, but levels that are similar to those that the astrocytes themselves accumulate after oxidative or thermal stress (MW Head, L Hurwitz, KB Kegel, and JE Goldman, submitted). Thus, the adenoviral gene transfer does not increase αB-crystallin levels above a range observed in stress conditions.
Figure 6.
Expression of αB-crystallin and β-Gal in RSV-hGF transfected mouse astrocytes. Two days after transfection with RSVi-hGF, astrocytes were infected with either αB-crystallin or β-Gal expression adenovirus vector. Organization of hGFAP was observed 3 days after the adenovirus infection. Representative results are presented. A and B: β-Gal expression. A cell expressing β-Gal (A) shows small hGFAP inclusions (B). C and D: αB-crystallin expression. An exogenous αB-crystallin-expressing cell (C) shows filamentous hGFAP (D). Bar, 20 μm.
To examine the effects of αB-crystallin on the formation and maintenance of the GFAP inclusions, we performed two sets of experiments. In the first, astrocytes were initially transfected with the hGFAP vector to generate inclusions. Three days after transfection, levels of αB-crystallin were increased by infecting the cultures with αBSAD. We then examined those cells that contained both hGFAP and increased αB-crystallin and compared them with cultures that had not been exposed to the adenovirus. In controls, ∼70% of the hGFAP-expressing cells contained inclusions, whereas in the αB-crystallin-adenovirus infected cells, only 30% contained inclusions, with the remaining 70% displaying a filamentous pattern (Table 2) ▶ . An additional decrease in the proportion of inclusion-bearing cells was not found 7 days after the αB-crystallin adenovirus infection. In the second set of experiments, astrocytes were first infected with αBSAD and then, 3 days later, transfected with the hGFAP vector. The proportion of astrocytes containing inclusions was also substantially decreased compared with controls (Table 2) ▶ . As an additional control, we substituted a β-Gal adenovirus, β-GalAD, for the αBSAD and found no decrease in the proportion of hGFAP-expressing astrocytes that contained inclusions. Thus, adenovirus infection per se does not alter IF organization and inclusion formation.
Table 2.
Effects of Adenovirus-Mediated αB-Crystallin and β-Gal Expression on hGFAP Inclusions in Mouse Cultured Astrocytes
Adenovirus infection | Inclusion-bearing cells (% total hGFAP-expressing cells) | ||
---|---|---|---|
None | β-Gal | αB-crystallin | |
Exp. 1: Adenovirus infection after inclusion formation | |||
3 days (5) | 73.2 ± 3.1 | 70.6 ± 1.9 | 34.3 ± 1.2* |
7 days (4) | 68.5 ± 4.7 | 69.4 ± 1.8 | 32.4 ± 3.7† |
Exp. 2: Adenovirus infection before inclusion formation | |||
2 days (3) | 76.5 ± 3.0 | 73.4 ± 1.3 | 46.1 ± 1.6† |
For experiment (Exp.) 1, cultured astrocytes were transfected with RSVi-hGF. Two days after the transfection, the cells were infected with either β-Gal or αB-crystallin gene carrying adenovirus. Organization of hGFAP in astrocytes expressing β-Gal or exogenous αB-crystallin was observed 3 and 7 days after the adenovirus infection. In each experiment, more than 100 cells were observed. For experiment 2, astrocytes were first infected with the adenovirus vectors. Three days after the adenovirus infection, the cells were transfected with RSVi-hGF. Organization of hGFAP was observed 2 days after the transfection. In each experiment, more than 50 cells were observed. Irrespective of the size and number of inclusions, a cell with visible inclusions was scored as inclusion-bearing cell. The numbers of inclusion-bearing cells are expressed as the percentage of total astrocytes expressing hGFAP. Results are mean ± SEM, and statistical analysis was made by Student’s t-test. Numbers of independent experiments are given in parentheses.
*P < 0.001 versus none.
†P < 0.01 versus none.
Discussion
Possible Mechanisms for Inclusion Formation
In this study, hGFAP introduced into mouse astrocytes produced two distinct types of cytoskeletal structures, filamentous and inclusion forms (Figure 1) ▶ . Before our experiments, exogenous GFAP had been found to be expressed in several cell types, 26,29-31 but in all cases, the GFAP polymerized into the endogenous IF network, and inclusions were not reported. We found that the susceptibility of hGFAP inclusion formation varied among different cell types (Table 1) ▶ . Thus, in addition to differences in gene transfer methods, the types of host cells may explain the different results from the previous studies.
The discrete GFAP inclusions are reminiscent of the IF aggregation produced by microtubule disrupting agents. 32-34 IF spreading is likely to be maintained by a mutual association between IFs and microtubules via linking proteins. The nature of these linking proteins is not clear, but they may include the so-called IF-associated proteins (IFAPs) 35-38 or members of the kinesin family of molecular motors. 39 We noted, however, that the endogenous networks of microtubules in the GFAP inclusion-bearing astrocytes appeared to be maintained normally (Figure 3) ▶ and, furthermore, that in some astrocytes, the added GFAP was incorporated into a spread IF network. In other cells, both inclusions and filamentous forms co-existed (Figure 1) ▶ . These results indicate that the ability to organize the endogenous IF network was not impaired by the inclusion formation. Thus, one possible mechanism for inclusion formation is that the amount of the added GFAP was excessive in relation to microtubules and IFAPs and could not be maintained in a spread form, resorting to the default, inclusion form. The proportion of cells that formed inclusions varied with the cell type, being lowest in NIH3T3 cells and highest in C6 cells (Table 1) ▶ . This may reflect higher ratios of microtubules to IFs in the 3T3 cells than in astrocytes, but additional studies should be performed before a clear conclusion can be drawn.
Another possible mechanism for inclusion formation is that they result from a defective interaction between the endogenous mouse IF proteins and the human GFAP. In fact, despite a high homology (∼90% identity) as a whole, 40 the amino acid sequence of hGFAP shows the most difference from mouse GFAP in the amino-terminal head domain, which is responsible for assembly characteristics of GFAP proteins. 26,41 However, the formation of inclusions did not depend on differences in species, as inclusions were present after adding mouse GFAP to mouse astrocytes (Figure 2D) ▶ . Therefore, it is likely thatinclusions were induced by an excess accumulation of GFAP molecules in the cells per se, rather than by differences in the GFAP protein sequences among species.
αB-Crystallin Disaggregates IF Inclusions
We had initially thought that the introduction of αB-crystallin by a recombinant adenovirus vector to the GFAP inclusion-bearing astrocytes might result in RF formation. This idea was predicated on a quantitative model in which high levels of small hsps would deposit on IF bundles. Indeed, it might be possible to generate RFs by this method, but if so, we have not yet reached a critical threshold for small hsp aggregation on the IFs. However, instead of forming RFs, the introduction of αB-crystallin markedly decreased the percentage of astrocytes that contained inclusions, apparently converting the hGFAP from an aggregate form to a normal filamentous organi-zation (Table 2) ▶ . We suggest that this conversion is due to a disaggregation or debundling of polymerized IFs and does not occur through a depolymerization-repolymerization cycle. The reason for this inference is that overexpression of αB-crystallin in normal astrocytes (without hGFAP transfection) had no effect on the detergent solubility of the endogenous GFAP (MW Head, L Hurwitz, KB Kegel, and JE Goldman, submitted). Although αB-crystallin inhibits GFAP polymerization in vitro, 13 our observations suggest that the effects of αB-crystallin on IF states in vivo has more to do with organization of IFs than with the polymerization state. For the experiments reported here, however, the transfection efficiency with hGFAP was too low to allow us to perform biochemical determinations of hGFAP polymerization states after infection with the αB-crystallin adenovirus.
The idea that αB-crystallin in some way organizes IFs is strongly supported by a recent finding of Vicart et al on a desmin-related myopathy (DRM), 42 a disease characterized by formation of desmin aggregates in muscle cells. They found a mutation of the αB-crystallin gene in DRM patients and showed that introduction of the mutated αB-crystallin induced cytoplasmic inclusions composed of desmin and αB-crystallin in muscle cell lines. αB-crystallin is normally associated with IFs in several cell types 12-14 and therefore might act as an IFAP, although it is not clear whether this is a direct interaction or whether it is mediated by other proteins. A study on fibroblasts from patients of giant axonal neuropathy, a disease characterized by IF-containing inclusion formation in various types of cells, suggested that some inducible protein factors convert the IF aggregates to filamentous structures. 43 αB-crystallin may be one of such inducible factors.
In a variety of neuropathologies it is common to see hypertrophic astrocytes with accumulated IFs in cell body and processes. The expression of αB-crystallin in astrocytes is also increased in many pathological conditions. 44-46 The increased αB-crystallin and IF proteins result in formation of RFs in astrocytes of Alexander disease, chronic glial scars, and low-grade fibrillary astrocytomas. 18-20 Observations in the hGFAP-overexpressing mouse indicate directly that the accumulation of IFs up-regulates small hsp expression (see Introduction). Thus, the present results suggest that one of the functions of αB-crystallin is to assist in maintaining the IF network and, if the network is disrupted, to play a role in rearrangement to a normal state.
Acknowledgments
We thank Dr. Ronald Liem for expression vectors, Dr. Michael Brenner for the mouse GFAP cDNA clone, and Drs. Jody Martin and Wolfgang Dillmann for the adenovirus vectors. We also thank Kristy Brown for the electron microscopy and Drs. Mark Head, Ronald Liem, and Michael Shelanski for their many helpful discussions.
Footnotes
Address reprint requests to Dr. J.E. Goldman, Department of Pathology, Columbia University College of Physicians and Surgeons, 630W, 168th Streey, New York, NY 10032. E-mail:jeg5@columbia.edu.
Supported by NIH grant EY-09331 to J.E. Goldman.
Y. Koyama’s present address: Department of Pharmacology, Faculty of Pharmaceutical Sciences, Osaka University, 1–6 Yamada-Oka Suita, 565, Japan.
References
- 1.Iwaki T, Kume-Iwaki A, Liem RKH, Goldman J: αB-crystallin is expressed in non-lenticular tissue and accumulates in Alexander’s disease. Cell 1989, 57:71-78 [DOI] [PubMed] [Google Scholar]
- 2.Bhat SP, Nagineni CN: αB subunit of lens-specific protein α-crystallin is present in other ocular and non-ocular tissue. Biochem Biophys Res Commun 1989, 158:319-325 [DOI] [PubMed] [Google Scholar]
- 3.Dubin RA, Wawrousek EF, Piatigorsky J: Expression of the murine αB-crystallin gene is not restricted to the lens. Mol Cell Biol 1989, 9:1083-1091 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Aoyama A, Frohli E, Schafere R, Klemenz R: αB-crystallin expression in mouse NIH3T3 fibroblasts: glucocorticoid responsiveness and involvement in thermal protection. Mol Cell Biol 1993, 13:1824-1835 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Klemenz R, Andres A-C, Frohli E, Schafer R, Aoyama A: Expression of the murine small heat shock proteins hsp25 and αB crystallin in the absence of stress. J Cell Biol 1993, 120:639-645 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Head MW, Corbin E, Goldman JE: Coordinate and independent regulation of αB-crystallin and HSP27 expression in response to physiological stress. J Cell Physiol 1994, 159:41-50 [DOI] [PubMed] [Google Scholar]
- 7.Horwitz J: α-Crystallin can function as a molecular chaperone. Proc Natl Acad Sci USA 1992, 89:10449-10453 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Iwaki T, Iwaki A, Tateishi J, Goldman JE: Sense and antisense modification of glial αB-crystallin production results in alterations of stress fiber formation and thermoresistance. J Cell Biol 1994, 125:1385-1393 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kegel KB, Iwaki A, Iwaki T, Goldman JE: αB-crystallin protects glial cells from hypertonic stress. Am J Physiol 1996, 270:C903-C909 [DOI] [PubMed] [Google Scholar]
- 10.Liang P, MacRae TH: Molecular chaperones and the cytoskeleton. J Cell Sci 1997, 110:1431-1440 [DOI] [PubMed] [Google Scholar]
- 11.Wang K, Spector A: α-Crystallin stabilizes actin filaments and prevents cytochalasin-induced depolymerization in a phosphorylation-dependent manner. Eur J Biochem 1996, 242:56-66 [DOI] [PubMed] [Google Scholar]
- 12.Bennardini F, Wrzosek A, Chiesi M: αB-crystallin in cardiac tissue: association with actin and desmin filaments. Circ Res 1992, 71:288-294 [DOI] [PubMed] [Google Scholar]
- 13.Nicholl ID, Quinlan RA: Chaperone activity of α-crystallins modulates intermediate filament assembly. EMBO J 1994, 13:945-953 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Wisniewski T, Goldman JE: αB-crystallin is associated with intermediate filaments in astrocytoma cells. Neurochem Res 1998, 23:385-392 [DOI] [PubMed] [Google Scholar]
- 15.Hazan R, Denk H, Franke WW, Lackinger E, Schiller DL: Change of cytokeratin organization during development of Mallory bodies as revealed by a monoclonal antibody. Lab Invest 1986, 54:543-553 [PubMed] [Google Scholar]
- 16.Bergeron C, Dickson DW, Pollanen MS: Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993, 52:183-191 [DOI] [PubMed] [Google Scholar]
- 17.Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, Landon M, Mayer RJ: Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson’s disease, Pick’s disease, and Alzheimer’s disease, as well as Rosenthal fibers in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 1988, 155:9-15 [DOI] [PubMed] [Google Scholar]
- 18.Grcevic N, Yates PO: Rosenthal fibers in tumours of the central nervous system. J Pathol Bacteriol 1957, 73:467-472 [Google Scholar]
- 19.Herndon RM, Rubinstein LJ, Freeman JM: Light and electron microscopic observations on Rosenthal fibers in Alexander’s disease and in multiple sclerosis. J Neuropathol Exp Neurol 1970, 29:524-551 [DOI] [PubMed] [Google Scholar]
- 20.Chin SS-M, Goldman JE: Glial inclusions in CNS degenerative diseases. J Neuropathol Exp Neurol 1996, 55:499-508 [DOI] [PubMed] [Google Scholar]
- 21.Tomokane N, Iwaki T, Tateishi J, Iwaki A, Goldman JE: Rosenthal fibers share epitopes with αB-crystallin, glial fibrillary acidic protein, and ubiquitin, but not with vimentin: immunoelectron microscopy with colloidal gold. Am J Pathol 1991, 138:875-885 [PMC free article] [PubMed] [Google Scholar]
- 22.Lowe J, McDermott H, Pike I, Spendlove I, Landon M, Mayer J: αB-crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease. J Pathol 1992, 166:61-68 [DOI] [PubMed] [Google Scholar]
- 23.Kato S, Hirano A, Umehara T, Kato M, Herz R, Ohama E: Comparative immunohistochemical study on the expression of αB-crystallin, ubiquitin and stress-response protein 27 in ballooned neurons in various disorders. Neuropathol Appl Neurobiol 1992, 18:335-340 [DOI] [PubMed] [Google Scholar]
- 24.Messing A, Head MW, Galles K, Galbreath EJ, Goldman JE, Brenner M: Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice. Am J Pathol 1998, 152:391-398 [PMC free article] [PubMed] [Google Scholar]
- 25.Eng LF, Lee YL, Kwan H, Brenner M, Messing A: Astrocytes cultured from transgenic mice carrying the added human glial fibrillary acidic protein gene contain Rosenthal fibers. J Neurosci Res 1998, 53:353-360 [DOI] [PubMed] [Google Scholar]
- 26.Chen W-J, Liem RKH: The endless story of the glial fibrillary acidic protein. J Cell Sci 1994, 107:2299-2311 [DOI] [PubMed] [Google Scholar]
- 27.Martin JD, Mestril R, Hilal-Dandan R, Brunton LL, Dillmann WH: Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 1997, 96:4343-4348 [DOI] [PubMed] [Google Scholar]
- 28.Chiu FC, Goldman JE: Synthesis and turnover of cytoskeletal proteins in cultured astrocytes. J Neurochem 1984, 42:166-174 [DOI] [PubMed] [Google Scholar]
- 29.Toda M, Miura M, Asou H, Toya S, Ueyama K: Cell growth suppression of astrocytoma C6 cells by glial fibrillary acidic protein cDNA transfection. J Neurochem 1994, 63:1975-1978 [DOI] [PubMed] [Google Scholar]
- 30.Murakami M, Fukuyama Hubbard S, Matsuzawa K, Dirks PB, Rutka JT: Inducible expression of glial fibrillary acidic protein in HT-1080 human fibrosarcoma cells. Cell Growth Differ 1996, 7:1697-1703 [PubMed] [Google Scholar]
- 31.Rutka JT, Smith S-L: Transfection of human astrocytoma cells with glial fibrillary acidic protein complementary DNA: analysis of expression, proliferation, and tumorigenicity. Cancer Res 1993, 53:3624-3631 [PubMed] [Google Scholar]
- 32.Forry-Schaudies S, Murry JM, Toyama Y, Holtzer H: Effects of colcemid and taxol on microtubules and intermediate filaments in chick embryo fibroblasts. Cell Motil Cytoskel 1986, 6:324-338 [DOI] [PubMed] [Google Scholar]
- 33.Geuens G, de Brabander M, Nuydens R, de Mey J: The interaction between microtubules and intermediate filaments in cultured cells treated with taxol and nocodazole. Cell Biol Int Rep 1983, 7:35-47 [DOI] [PubMed] [Google Scholar]
- 34.Blose SH, Meltzer DJ, Feramisco JR: 10 nm Filaments are induced to collapse in living cells microinjected with monoclonal and polyclonal antibodies against tubulin. J Cell Biol 1984, 98:847-858 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Bloom GS, Vallee RB: Association of microtubule-associated protein 2 (MAP2) with microtubules and intermediate filaments in cultured brain cells. J Cell Biol 1983, 96:1523-1531 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Lin JJ-C, Feramisco JR: Disruption of the in vitro distribution of the intermediate filaments in fibroblasts through the microinjection of a specific monoclonal antibody. Cell 1981, 24:185-193 [DOI] [PubMed] [Google Scholar]
- 37.Draberova E, Draber P: A microtubule-interacting protein involved in coalignment of vimentin intermediate filaments with microtubules. J Cell Biol 1993, 106:1263-1273 [DOI] [PubMed] [Google Scholar]
- 38.Foisner R, Wiche G: Intermediate filament-associated proteins. Curr Opin Cell Biol 1991, 3:75-81 [DOI] [PubMed] [Google Scholar]
- 39.Liao G, Gundersen GG: Kinesin is a candidate for cross-bridging microtubules and intermediate filaments: selective binding of kinesin to detyrosinated tubulin and vimentin. J Biol Chem 1998, 273:9797-9803 [DOI] [PubMed] [Google Scholar]
- 40.Brenner M, Lampel K, Nakatani Y, Mill J, Banner C, Mearow K, Dohadwala M, Lipsky R, Freese E: Characterization of human cDNA and genomic clone for glial fibrillary acidic protein. Brain Res 1990, 7:277-286 [DOI] [PubMed] [Google Scholar]
- 41.Ralton JE, Lu X, Hutcheson AM, Quinlan RA: Identification of two N-terminal non-α-helical domain motifs important in the assembly of glial acidic protein. J Cell Sci 1994, 107:1935-1948 [DOI] [PubMed] [Google Scholar]
- 42.Vicart P, Caron A, Guicheney P, Li Z, Prevost M-C, Faure A, Chateau D, Chapon F, Tome F, Dupret J-M, Paulin D, Fardeau M: A missense mutation in the αB-crystallin chaperone gene causes a desmin-related myopathy. Nature Genet 1998, 20:92-95 [DOI] [PubMed] [Google Scholar]
- 43.Klymkowsky MW, Plummer DJ: Giant axonal neuropathy: a conditional mutation affecting cytoskeletal organization. J Cell Biol 1985, 100:245-250 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Iwaki T, Wisniewski T, Iwaki A, Corbin E, Tomokane N, Tateishi J, Goldman JE: Accumulation of αB-crystallin in central nervous system glia and neurons in pathological conditions. Am J Pathol 1992, 140:345-356 [PMC free article] [PubMed] [Google Scholar]
- 45.Renkawek K, de Jong WW, Merck KB, Frenken CWGM, van Workum FPA, Bosman GJCGM: αB-crystallin is present in reactive glia in Creutzfeldt-Jakob disease. Acta Neuropathol 1992, 83:324-327 [DOI] [PubMed] [Google Scholar]
- 46.Renkawek K, Voorter CEM, Bosman GJCG, van Workum FPA, de Jong WW: Expression of αB-crystallin in Alzheimer’s disease. Acta Neuropathol 1994, 878:155-160 [DOI] [PubMed] [Google Scholar]